Insight Molecular Diagnostics(DE:7OC0)
€2.200.00 (0.00%)
DE:7OC0
Insight Molecular Diagnostics financials statements
€2.20
At close:0.00 (0.00%)
Insight Molecular Diagnostics (7OC0) Ratios
1 Followers
Insight Molecular Diagnostics Ratios
DE:7OC0's free cash flow for Q2 2026 was $-10.05M. For the 2026 fiscal year, DE:7OC0's free cash flow was decreased by $-779.00K and operating cash flow was $-9.27M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Mar 24 | Mar 23 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 1.27 | 1.62 | 1.49 | 2.11 | 2.77 |
| Quick Ratio | 1.23 | 1.56 | 1.49 | 2.11 | 2.75 |
| Cash Ratio | 0.96 | 1.19 | 1.31 | 1.65 | 2.33 |
| Solvency Ratio | -0.84 | -1.25 | -0.48 | -1.12 | -0.63 |
| Operating Cash Flow Ratio | -1.84 | -2.85 | -3.24 | -3.76 | -2.55 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | 0.00 | 0.00 | -27.37 |
| Net Current Asset Value | $ -41.91M | $ -35.60M | $ -43.73M | $ -34.96M | $ -55.20M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.14 | 0.10 | 0.04 | 0.04 | 0.04 |
| Debt-to-Equity Ratio | -0.11 | -0.30 | 0.14 | 0.09 | 0.09 |
| Debt-to-Capital Ratio | -0.13 | -0.43 | 0.12 | 0.08 | 0.08 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | -0.82 | -2.86 | 3.66 | 2.53 | 2.45 |
| Debt Service Coverage Ratio | -439.60 | -702.56 | -444.67 | -160.35 | -25.75 |
| Interest Coverage Ratio | -280.53 | -726.68 | -483.38 | -216.83 | -257.06 |
| Debt to Market Cap | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 |
| Interest Debt Per Share | 0.12 | 0.29 | 0.38 | 0.65 | 1.32 |
| Net Debt to EBITDA | 0.17 | 0.08 | 0.28 | 1.24 | 0.56 |
| Profitability Margins | |||||
| Gross Profit Margin | 4.69% | 39.34% | 27.48% | -1.88% | 64.60% |
| EBIT Margin | -1235.83% | -3220.57% | -1650.23% | -1934.13% | -2395.91% |
| EBITDA Margin | -1181.65% | -3137.43% | -1538.46% | -1389.25% | -2204.60% |
| Operating Profit Margin | -754.08% | -3245.14% | -1672.39% | -1878.60% | -2444.27% |
| Pretax Profit Margin | -1238.52% | -3225.04% | -1653.69% | -1942.80% | -2405.41% |
| Net Profit Margin | -1238.52% | -3225.04% | -1848.37% | -7609.81% | -2916.15% |
| Continuous Operations Profit Margin | -1238.52% | -3225.04% | -1653.69% | -1942.80% | -1984.08% |
| Net Income Per EBT | 100.00% | 100.00% | 111.77% | 391.69% | 121.23% |
| EBT Per EBIT | 164.24% | 99.38% | 98.88% | 103.42% | 98.41% |
| Return on Assets (ROA) | -194.99% | -172.92% | -37.09% | -72.84% | -40.17% |
| Return on Equity (ROE) | 159.62% | 494.24% | -135.73% | -184.12% | -98.28% |
| Return on Capital Employed (ROCE) | -223.51% | -219.52% | -37.13% | -20.45% | -36.94% |
| Return on Invested Capital (ROIC) | -197.43% | -209.76% | -36.77% | -20.27% | -30.03% |
| Return on Tangible Assets | -194.99% | -296.29% | -151.83% | -189.56% | -80.97% |
| Earnings Yield | -21.97% | -195.00% | -145.24% | -204.97% | -33.22% |
| Efficiency Ratios | |||||
| Receivables Turnover | 3.59 | 1.17 | 3.11 | 0.48 | 1.53 |
| Payables Turnover | 1.52 | 0.50 | 1.14 | 0.78 | 0.43 |
| Inventory Turnover | 8.67 | 2.78 | 0.00 | 0.00 | 2.56 |
| Fixed Asset Turnover | 1.44 | 0.68 | 0.28 | 0.09 | 0.26 |
| Asset Turnover | 0.16 | 0.05 | 0.02 | 0.01 | 0.01 |
| Working Capital Turnover Ratio | 1.05 | 0.47 | 0.18 | 0.05 | 0.17 |
| Cash Conversion Cycle | -96.60 | -284.89 | -201.59 | 297.99 | -467.91 |
| Days of Sales Outstanding | 101.53 | 313.00 | 117.54 | 766.58 | 238.63 |
| Days of Inventory Outstanding | 42.12 | 131.16 | 0.00 | 0.00 | 142.62 |
| Days of Payables Outstanding | 240.25 | 729.04 | 319.12 | 468.59 | 849.16 |
| Operating Cycle | 143.65 | 444.15 | 117.54 | 766.58 | 381.25 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.73 | -1.58 | -3.05 | -8.23 | -8.08 |
| Free Cash Flow Per Share | -0.83 | -1.62 | -3.09 | -9.01 | -8.59 |
| Dividend Paid and CapEx Coverage Ratio | -6.97 | -40.14 | -83.01 | -10.50 | -16.00 |
| Capital Expenditure Coverage Ratio | -6.97 | -40.14 | -83.01 | -10.50 | -16.00 |
| Operating Cash Flow Coverage Ratio | -6.34 | -5.65 | -8.13 | -12.86 | -6.33 |
| Operating Cash Flow to Sales Ratio | -5.47 | -11.01 | -15.52 | -47.57 | -16.35 |
| Free Cash Flow Yield | -11.10% | -68.24% | -123.41% | -140.32% | -19.79% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -4.55 | -0.51 | -0.69 | -0.49 | -3.01 |
| Price-to-Sales (P/S) Ratio | 56.37 | 16.54 | 12.73 | 37.13 | 87.79 |
| Price-to-Book (P/B) Ratio | -7.26 | -2.53 | 0.93 | 0.90 | 2.96 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -9.01 | -1.47 | -0.81 | -0.71 | -5.05 |
| Price-to-Operating Cash Flow Ratio | -10.30 | -1.50 | -0.82 | -0.78 | -5.37 |
| Price-to-Earnings Growth (PEG) Ratio | 0.07 | -0.02 | 0.01 | -0.01 | -0.05 |
| Enterprise Value Multiple | -4.60 | -0.44 | -0.54 | -1.44 | -3.42 |
| Enterprise Value | 220.48M | 26.14M | 12.56M | 19.12M | 165.69M |
| EV to EBITDA | -4.60 | -0.44 | -0.54 | -1.44 | -3.42 |
| EV to Sales | 54.37 | 13.90 | 8.36 | 19.96 | 75.38 |
| EV to Free Cash Flow | -8.69 | -1.23 | -0.53 | -0.38 | -4.34 |
| EV to Operating Cash Flow | -9.94 | -1.26 | -0.54 | -0.42 | -4.61 |
| Tangible Book Value Per Share | -1.03 | -2.06 | -4.72 | -3.98 | -3.42 |
| Shareholders’ Equity Per Share | -1.03 | -0.94 | 2.68 | 7.15 | 14.67 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.00 | 0.18 |
| Revenue Per Share | 0.13 | 0.14 | 0.20 | 0.17 | 0.49 |
| Net Income Per Share | -1.65 | -4.64 | -3.63 | -13.16 | -14.42 |
| Tax Burden | 1.00 | 1.00 | 1.12 | 3.92 | 1.21 |
| Interest Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Research & Development to Revenue | 3.92 | 5.23 | 6.18 | 7.62 | 2.29 |
| SG&A to Revenue | 4.19 | 7.33 | 8.63 | 22.46 | 9.28 |
| Stock-Based Compensation to Revenue | 0.55 | 1.02 | 4.37 | 10.48 | 3.11 |
| Income Quality | 0.44 | 0.34 | 0.84 | 0.63 | 0.56 |
Currency in USD
